Overexpression of Apolipoprotein CII Causes Hypertriglyceridemia in Transgenic Mice

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1994 Apr 1

PMID 8163669

Citations 34

Authors

N S Shachter

T Hayek

T Leff

J D Smith

D W Rosenberg

A Walsh

R Ramakrishnan

I J Goldberg

H N Ginsberg

J L Breslow

Affiliations

Soon will be listed here.

Abstract

We have generated transgenic mice expressing the human apolipoprotein CII (apoCII) gene under the transcriptional control of the human cytochrome P-450 IA1 (CYPIA1) promoter. Human apoCII transgenic (HuCIITg) mice exhibited significant basal expression of the transgene (plasma apoCII level = 26.1 +/- 4 mg/dl) and showed further induction of transgene expression after treatment with beta-naphthoflavone. Unexpectedly, HuCIITg mice were hypertriglyceridemic and human apoCII levels correlated strongly to triglyceride levels (R = 0.89, P < 0.0001). Triglyceride levels (mg/dl +/- SEM) were elevated compared to controls in both the fed (804 +/- 113 vs 146 +/- 18, P < 0.001) and fasted (273 +/- 39 vs 61 +/- 4, P < 0.001) states. HuCIITg mice accumulated triglyceride-rich very low density lipoproteins (VLDL) with an increased apoC/apoE ratio. Tracer kinetic studies indicated delayed clearance of VLDL-triglyceride, and studies using Triton inhibition of VLDL clearance showed no increase in VLDL production. Plasma from these mice activated mouse lipoprotein lipase normally and radiolabeled VLDL were normally hydrolyzed. However, HuCIITg VLDL showed markedly decreased binding to heparin-Sepharose, suggesting that apoCII-rich, apoE-poor lipoprotein may be less accessible to cell surface lipases or receptors within their glycosaminoglycan matrices. HuCIITg mice are a promising model of hypertriglyceridemia that suggests a more complex role for apoCII in the metabolism of plasma triglycerides.

Citing Articles

Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.

Reijnders E, van der Laarse A, Ruhaak L, Cobbaert C Clin Proteomics. 2024; 21(1):19.

PMID: 38429638 PMC: 10908091. DOI: 10.1186/s12014-024-09465-w.

Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease.

Liu G, Lai P, Guo J, Wang Y, Xian X Med Rev (2021). 2023; 1(1):92-110.

PMID: 37724074 PMC: 10388752. DOI: 10.1515/mr-2021-0004.

Quartet of APOCs and the Different Roles They Play in Diabetes.

Hsu C, Kanter J, Kothari V, Bornfeldt K Arterioscler Thromb Vasc Biol. 2023; 43(7):1124-1133.

PMID: 37226733 PMC: 10330679. DOI: 10.1161/ATVBAHA.122.318290.

Apolipoprotein C-II: a new look at an old protein.

Hegele R Eur Heart J. 2023; 44(25):2345-2347.

PMID: 37161516 PMC: 10314325. DOI: 10.1093/eurheartj/ehad237.

The Importance of Lipoprotein Lipase Regulation in Atherosclerosis.

Kumari A, Kristensen K, Ploug M, Lund Winther A Biomedicines. 2021; 9(7).

PMID: 34356847 PMC: 8301479. DOI: 10.3390/biomedicines9070782.

References

Ito Y, Azrolan N, OConnell A, Walsh A, Breslow J . Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990; 249(4970):790-3. DOI: 10.1126/science.2167514. View

BARTLETT G . Phosphorus assay in column chromatography. J Biol Chem. 1959; 234(3):466-8. View

Weisgraber K, Mahley R, Kowal R, Herz J, Goldstein J, Brown M . Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990; 265(36):22453-9. View

Rosenberg D . Tissue-specific induction of the carcinogen inducible cytochrome P450 isoform, P450IAI, in colonic epithelium. Arch Biochem Biophys. 1991; 284(1):223-6. DOI: 10.1016/0003-9861(91)90288-t. View

Weber K, Osborn M . The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969; 244(16):4406-12. View

Larosa J, Levy R, Herbert P, Lux S, Fredrickson D . A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun. 1970; 41(1):57-62. DOI: 10.1016/0006-291x(70)90468-7. View

Brown W, Baginsky M . Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972; 46(2):375-82. DOI: 10.1016/s0006-291x(72)80149-9. View

HAVEL R, Fielding C, Olivecrona T, SHORE V, Fielding P, Egelrud T . Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 1973; 12(9):1828-33. DOI: 10.1021/bi00733a026. View

Augustin J, Freeze H, Tejada P, Brown W . A comparison of molecular properties of hepatic triglyceride lipase and lipoprotein lipase from human post-heparin plasma. J Biol Chem. 1978; 253(9):2912-20. View

10.

Cox D, Breckenridge W, Little J . Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med. 1978; 299(26):1421-4. DOI: 10.1056/NEJM197812282992601. View

11.

Shelburne F, Hanks J, Meyers W, QUARFORDT S . Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980; 65(3):652-8. PMC: 371406. DOI: 10.1172/JCI109710. View

12.

Windler E, Chao Y, HAVEL R . Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem. 1980; 255(11):5475-80. View

13.

Shirai K, Matsuoka N, Jackson R . Interaction of lipoprotein lipase with phospholipid vesicles. Role of apolipoprotein C-II and heparin. Biochim Biophys Acta. 1981; 665(3):504-10. DOI: 10.1016/0005-2760(81)90264-2. View

14.

Feinberg A, Vogelstein B . A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983; 132(1):6-13. DOI: 10.1016/0003-2697(83)90418-9. View

15.

Jackson C, BRUNS G, Breslow J . Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII. Proc Natl Acad Sci U S A. 1984; 81(10):2945-9. PMC: 345197. DOI: 10.1073/pnas.81.10.2945. View

16.

Ginsberg H, Le N, Gibson J . Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J Clin Invest. 1985; 75(2):614-23. PMC: 423538. DOI: 10.1172/JCI111739. View

17.

Clark A, Quarfordt S . Apolipoprotein effects on the lipolysis of perfused triglyceride by heparin-immobilized milk lipase. J Biol Chem. 1985; 260(8):4778-83. View

18.

Jaiswal A, Gonzalez F, Nebert D . Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res. 1985; 13(12):4503-20. PMC: 321802. DOI: 10.1093/nar/13.12.4503. View

19.

Ishikawa Y, Fielding C, Fielding P . A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein. J Biol Chem. 1988; 263(6):2744-9. View

20.

Smit M, Woudt L, Havekes L, Frants R . Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem Biophys Res Commun. 1988; 152(3):1282-8. DOI: 10.1016/s0006-291x(88)80424-8. View